Ticagrelor (Brilinta) is an antiplatelet agent sometimes used in the prevention of recurrent ischemic stroke. While it was not shown to be superior to aspirin alone in large trials, combining ticagrelor with aspirin for 30 days after a minor stroke or high-risk TIA has been shown to reduce recurrent events, though at the cost of higher bleeding risk. It is generally considered in selected patients, particularly those with certain vascular risk profiles or intolerance to other antiplatelets. Ticagrelor requires twice-daily dosing and careful monitoring for bleeding. It is less commonly used than aspirin or clopidogrel for long-term secondary prevention.